# PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

> **NCT06423144** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TACE/HAIC
- **DRUG:** PD-1/PD-L1 inhibits and anti-angiogenic agents

## Key facts

- **NCT ID:** NCT06423144
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2024-08
- **Final completion:** 2024-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423144, "PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06423144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*